{"id":"W4391720973","doi":"10.1016/j.prdoa.2024.100239","title":"Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance","year":2024,"lang":"en","type":"article","venue":"Clinical Parkinsonism & Related Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Cégep de Lévis","funders":"Parkinsonfonden; LEO Pharma; Sun Pharma; Göteborgs Universitet; Sahlgrenska Universitetssjukhuset; University of Washington; Sage Therapeutics; Neurocrine Biosciences; Acorda Therapeutics; Ipsen; Jazz Pharmaceuticals; EVER Neuro Pharma; Michael J. Fox Foundation for Parkinson's Research; Revance; Boston Scientific Corporation; H. Lundbeck A/S; Sunovion; Washington State University; Parkinson's Foundation; Amneal Pharmaceuticals; Biogen; Pfizer; Northwestern University; F. Hoffmann-La Roche; Massachusetts General Hospital; Neuraxpharm; Teva Pharmaceutical Industries; US WorldMeds; Allergan; AstraZeneca; Eli Lilly and Company; Supernus Pharmaceuticals; AbbVie; Sanofi","keywords":"Medicine; Adverse effect; Dopaminergic; Intensive care medicine; Disease; Deep brain stimulation; Parkinson's disease; Physical medicine and rehabilitation; Internal medicine; Dopamine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003773539,0.0002974813,0.0005559596,0.0001752802,0.0002413721,0.00005865075,0.00006480756,0.0002041953,0.00004405092],"category_scores_gemma":[0.0009878913,0.000213018,0.0004577626,0.0002089181,0.0002596005,0.00009589616,0.00001932497,0.0001554859,0.000007494264],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001370111,"about_ca_system_score_gemma":0.0003432469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005982479,"about_ca_topic_score_gemma":0.0001591756,"domain_scores_codex":[0.9977536,0.0001095905,0.0009506519,0.0006393426,0.0001936738,0.0003531324],"domain_scores_gemma":[0.9952362,0.003850538,0.0001839008,0.0003603904,0.0001293037,0.0002396634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01235344,0.01128251,0.0602161,0.001146756,0.003830838,0.0005942854,0.003499209,0.0005878066,0.0009558377,0.03840224,0.004511714,0.8626193],"study_design_scores_gemma":[0.0166158,0.006207279,0.1457099,0.0005869493,0.002849142,0.00004742398,0.0004772341,0.07565124,0.00007161841,0.08281376,0.6684635,0.000506167],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9494935,0.02792858,0.004047105,0.0082536,0.001305737,0.007538769,0.0009250253,0.0001855329,0.000322128],"genre_scores_gemma":[0.9798349,0.01664552,0.001171767,0.0002371393,0.00009030916,0.001357257,0.0001872514,0.00005589255,0.0004199527],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8621131,"threshold_uncertainty_score":0.8686622,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02982233691540017,"score_gpt":0.3244813869106378,"score_spread":0.2946590499952377,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}